• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解析FUS::DDIT3表达和肿瘤微环境在黏液样脂肪肉瘤发生发展中的作用。

Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.

作者信息

Ranji Parmida, Jonasson Emma, Andersson Lisa, Filges Stefan, Luna Santamaría Manuel, Vannas Christoffer, Dolatabadi Soheila, Gustafsson Anna, Myklebost Ola, Håkansson Joakim, Fagman Henrik, Landberg Göran, Åman Pierre, Ståhlberg Anders

机构信息

Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.

出版信息

J Transl Med. 2024 Apr 26;22(1):389. doi: 10.1186/s12967-024-05211-w.

DOI:10.1186/s12967-024-05211-w
PMID:38671504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11046918/
Abstract

BACKGROUND

Myxoid liposarcoma (MLS) displays a distinctive tumor microenvironment and is characterized by the FUS::DDIT3 fusion oncogene, however, the precise functional contributions of these two elements remain enigmatic in tumor development.

METHODS

To study the cell-free microenvironment in MLS, we developed an experimental model system based on decellularized patient-derived xenograft tumors. We characterized the cell-free scaffold using mass spectrometry. Subsequently, scaffolds were repopulated using sarcoma cells with or without FUS::DDIT3 expression that were analyzed with histology and RNA sequencing.

RESULTS

Characterization of cell-free MLS scaffolds revealed intact structure and a large variation of protein types remaining after decellularization. We demonstrated an optimal culture time of 3 weeks and showed that FUS::DDIT3 expression decreased cell proliferation and scaffold invasiveness. The cell-free MLS microenvironment and FUS::DDIT3 expression both induced biological processes related to cell-to-cell and cell-to-extracellular matrix interactions, as well as chromatin remodeling, immune response, and metabolism. Data indicated that FUS::DDIT3 expression more than the microenvironment determined the pre-adipocytic phenotype that is typical for MLS.

CONCLUSIONS

Our experimental approach opens new means to study the tumor microenvironment in detail and our findings suggest that FUS::DDIT3-expressing tumor cells can create their own extracellular niche.

摘要

背景

黏液样脂肪肉瘤(MLS)具有独特的肿瘤微环境,其特征为FUS::DDIT3融合致癌基因,然而,这两个因素在肿瘤发展中的确切功能贡献仍不明确。

方法

为研究MLS中的无细胞微环境,我们基于去细胞化的患者来源异种移植肿瘤开发了一个实验模型系统。我们使用质谱对无细胞支架进行了表征。随后,使用表达或不表达FUS::DDIT3的肉瘤细胞重新接种支架,并通过组织学和RNA测序进行分析。

结果

对无细胞MLS支架的表征显示其结构完整,去细胞化后残留的蛋白质类型差异很大。我们证明了最佳培养时间为3周,并表明FUS::DDIT3表达降低了细胞增殖和支架侵袭性。无细胞MLS微环境和FUS::DDIT3表达均诱导了与细胞间和细胞与细胞外基质相互作用以及染色质重塑、免疫反应和代谢相关的生物学过程。数据表明,FUS::DDIT3表达比微环境更能决定MLS典型的前脂肪细胞表型。

结论

我们的实验方法为详细研究肿瘤微环境开辟了新途径,我们的研究结果表明,表达FUS::DDIT3的肿瘤细胞可以创造自己的细胞外生态位。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/1918f7337e38/12967_2024_5211_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/3d9f1897d2a8/12967_2024_5211_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/819e02170436/12967_2024_5211_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/1a9c04d98080/12967_2024_5211_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/1918f7337e38/12967_2024_5211_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/3d9f1897d2a8/12967_2024_5211_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/819e02170436/12967_2024_5211_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/1a9c04d98080/12967_2024_5211_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ccf/11046918/1918f7337e38/12967_2024_5211_Fig4_HTML.jpg

相似文献

1
Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.解析FUS::DDIT3表达和肿瘤微环境在黏液样脂肪肉瘤发生发展中的作用。
J Transl Med. 2024 Apr 26;22(1):389. doi: 10.1186/s12967-024-05211-w.
2
Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.FUS-DDIT3 型黏液样脂肪肉瘤中 FLT1 的核表达及其配体 PGF 提示存在一个内源性信号环路。
BMC Cancer. 2010 Jun 1;10:249. doi: 10.1186/1471-2407-10-249.
3
The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.黏液样/圆形细胞脂肪肉瘤融合致癌基因FUS-DDIT3和正常DDIT3在转染的人纤维肉瘤细胞中诱导脂肪肉瘤表型。
Am J Pathol. 2006 May;168(5):1642-53. doi: 10.2353/ajpath.2006.050872.
4
FUS::DDIT3 Fusion Protein in the Development of Myxoid Liposarcoma and Possible Implications for Therapy.FUS::DDIT3 融合蛋白在黏液样脂肪肉瘤的发生发展中的作用及其对治疗的可能影响。
Biomolecules. 2024 Oct 14;14(10):1297. doi: 10.3390/biom14101297.
5
Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.脂肪肉瘤中FUS-DDIT3融合癌基因的调控机制、表达水平及增殖效应
J Pathol. 2016 Apr;238(5):689-99. doi: 10.1002/path.4700.
6
Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma.利用 WEE1 激酶活性作为 FUS::DDIT3 依赖性治疗靶点治疗黏液样脂肪肉瘤。
Clin Cancer Res. 2024 Nov 1;30(21):4974-4986. doi: 10.1158/1078-0432.CCR-24-1152.
7
Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.采用联合 DNA、mRNA 和蛋白质分析鉴定黏液样脂肪肉瘤中调节细胞增殖和 FUS-DDIT3 表达的抑制剂。
Lab Invest. 2018 Jul;98(7):957-967. doi: 10.1038/s41374-018-0046-3. Epub 2018 Mar 27.
8
The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.黏液样脂肪肉瘤FUS-DDIT3融合癌蛋白通过与NFKBIZ相互作用来失调NF-κB靶基因。
Oncogene. 2009 Jan 15;28(2):270-8. doi: 10.1038/onc.2008.378. Epub 2008 Oct 13.
9
DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.DNA损伤诱导转录因子3/CCAAT增强子结合蛋白同源蛋白(DDIT3/CHOP)和肉瘤融合致癌蛋白FUS-DDIT3/ TLS-CHOP与细胞周期蛋白依赖性激酶2结合。
BMC Cell Biol. 2009 Dec 17;10:89. doi: 10.1186/1471-2121-10-89.
10
Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.黏液样脂肪肉瘤FUS-DDIT3融合癌基因诱导C/EBPβ介导的白细胞介素6表达。
Int J Cancer. 2005 Jul 1;115(4):556-60. doi: 10.1002/ijc.20893.

引用本文的文献

1
Breast cancer patient-derived scaffolds enhance the understanding of PD-L1 regulation and T cell cytotoxicity.乳腺癌患者来源的支架增强了对PD-L1调节和T细胞细胞毒性的理解。
Commun Biol. 2025 Apr 16;8(1):621. doi: 10.1038/s42003-025-08054-3.
2
An Incidental Finding of Gain of a Diminished Chromosome 12 Centromere in an Individual with Lymphocytosis: A Case Report and Clinical Implications in Cytogenetic Testing.淋巴细胞增多个体中意外发现12号染色体着丝粒减少性增加:一例报告及细胞遗传学检测的临床意义
Diagnostics (Basel). 2025 Mar 4;15(5):618. doi: 10.3390/diagnostics15050618.

本文引用的文献

1
Proteomics of cell-free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer-progressing properties.游离乳腺癌支架的蛋白质组学鉴定出临床相关的印记蛋白和癌症进展特性。
Cancer Commun (Lond). 2024 Jun;44(6):695-699. doi: 10.1002/cac2.12542. Epub 2024 Apr 4.
2
Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties of the Cancer Microenvironment Associated with Clinical Characteristics.乳腺癌患者来源的支架可揭示与临床特征相关的癌症微环境独特的个体癌症进展特性。
Cancers (Basel). 2022 Apr 26;14(9):2172. doi: 10.3390/cancers14092172.
3
5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information.
5-氟尿嘧啶处理源自结直肠癌患者的支架揭示了临床关键信息。
J Transl Med. 2022 May 13;20(1):209. doi: 10.1186/s12967-022-03423-6.
4
The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.FUS::DDIT3 融合癌蛋白抑制黏液样脂肪肉瘤中 BAF 复合物的靶向和活性。
Mol Cell. 2022 May 5;82(9):1737-1750.e8. doi: 10.1016/j.molcel.2022.03.019. Epub 2022 Apr 6.
5
FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.FUS-DDIT3融合癌蛋白表达影响黏液样脂肪肉瘤中的JAK-STAT信号通路。
Front Oncol. 2022 Feb 3;12:816894. doi: 10.3389/fonc.2022.816894. eCollection 2022.
6
Patient-derived scaffolds as a drug-testing platform for endocrine therapies in breast cancer.患者来源的支架作为乳腺癌内分泌治疗药物测试平台。
Sci Rep. 2021 Jun 25;11(1):13334. doi: 10.1038/s41598-021-92724-9.
7
Integrated analysis of multimodal single-cell data.多模态单细胞数据的综合分析。
Cell. 2021 Jun 24;184(13):3573-3587.e29. doi: 10.1016/j.cell.2021.04.048. Epub 2021 May 31.
8
Optimized alginate-based 3D printed scaffolds as a model of patient derived breast cancer microenvironments in drug discovery.优化的藻酸盐基 3D 打印支架作为药物发现中患者来源的乳腺癌微环境模型。
Biomed Mater. 2021 Jun 25;16(4). doi: 10.1088/1748-605X/ac0451.
9
Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas.人类白细胞抗原 I 在黏液样脂肪肉瘤患者中显著下调。
Cancer Immunol Immunother. 2021 Dec;70(12):3489-3499. doi: 10.1007/s00262-021-02928-1. Epub 2021 Apr 24.
10
Patient-derived scaffolds as a model of colorectal cancer.患者来源的支架作为结直肠癌模型。
Cancer Med. 2021 Feb;10(3):867-882. doi: 10.1002/cam4.3668. Epub 2020 Dec 23.